12:00 AM
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

INGN 241 (Adenoviral-mda-7): Began Phase I trial

Introgen Therapeutics Inc. (INGN), Austin, Texas
Product: INGN 241 (Adenoviral-mda-7)
Business: Cancer, Gene/Cell therapy
Therapeutic category: Gene therapy, Apoptosis
Target: Tumor cells

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >